U.S. FDA declines to approve Blueprint"s therapy for type of stomach cancer

FDA declines to approve Daiichi Sankyo"s blood cancer treatment.....»»

Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia.....»»

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy.....»»

Novartis gene therapy approval signals new cancer treatment era.....»»

Novartis approval for gene therapy signals new cancer treatment era.....»»

U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma.....»»

Zydus Cadila launches generic prostate cancer drug at nearly 70% less price in India.....»»

U.S. FDA extends review of Bristol Myers" cancer therapy acquired in Celgene deal.....»»

Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty.....»»

"Waiting game" for Oregon patient needing cancer surgery amid coronavirus.....»»

AstraZeneca"s Imfinzi gets FDA nod to target small-cell lung cancer.....»»

GIOSTAR Launches Stem Cell / Cancer Research and Therapy Center in Chandigarh, India.....»»

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA.....»»

Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck.....»»

Immunotherapy Emerging as a Treatment of Hope for Those With Lung Cancer.....»»

Housing Absorption Declines 13% in Q2 2019, New Launches Down 2% - ANAROCK.....»»

FDA declines to approve Acer Therapeutics" treatment for rare genetic disorder.....»»

AstraZeneca"s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment.....»»

Over 1.5 crore people will need chemotherapy globally each year by 2040: Study.....»»

Novartis confident of Zolgensma supply, calls $2 million price "speculation".....»»